Page 1

✔ 0 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington , D.C. 20549 FORM 10 - K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31 , 2020 Transition Report Pursuant to Section 13 or 15 ( d ) of the Securities Exchange Act of 1934 Commission File Number : 001-36257 TRAVERE THERAPEUTICS , INC . ( Exact Name of Registrant as specified in its Charter ) Delaware ( State or other jurisdiction of incorporation or organization ) Title of each class Common Stock , par value $ 0.0001 per share 3611 Valley Centre Drive , Suite 300 San Diego , CA 92130 ( Address of Principal Executive Offices ) 888-969-7879 27-4842691 ( I.R.S. Employer Identification No. ) ( Registrant's telephone number , including area code ) Securities registered pursuant to Section 12 ( b ) of the Act : Trading Symbol ( s ) TVTX Name of each exchange on which registered The Nasdaq Global Market Securities registered pursuant to Section 12 ( g ) of the Act : None Indicate by check mark if the registrant is a well - known seasoned issuer , as defined in Rule 405 of the Securities Act . Yes □ No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15 ( d ) of the Act . □ Yes No Indicate by check mark whether the registrant : ( 1 ) has filed all reports required to be filed by Section 13 or 15 ( d ) of the Securities Exchange Act of 1934 during the preceding 12 months ( or for such shorter period that the registrant was required to file such reports ) , and ( 2 ) has been subject to such filing requirements for the past 90 days . Yes □ No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S - T during the preceding 12 months ( or for such shorter period that the registrant was required to submit such files ) . Yes □ No